Announcements
- Bavarian Nordic Submits Supplemental BLA Seeking U.S. FDA Approval of Freeze-Dried Formulation of Smallpox and Mpox Vaccine
- Bavarian Nordic indsender supplerende ansøgning til de amerikanske sundhedsmyndigheder om godkendelse af frysetørret koppe- og mpoxvaccine
- Bavarian Nordic and CEPI Partners to Advance Mpox Vaccination in Africa
- Bavarian Nordic og CEPI indgår partnerskab om mpox-vaccinationer i Afrika
- Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
- Kapitalforhøjelse i Bavarian Nordic A/S som følge af medarbejderes udnyttelse af tegningsoptioner
- Bavarian Nordic – Transactions in Connection with Share Buy-Back Program and Termination of Share Buy-Back Program
- Bavarian Nordic – transaktioner i forbindelse med aktietilbagekøbsprogram samt ophør af aktietilbagekøbsprogram
- EVP and Chief Medical Officer Laurence de Moerlooze Will Be Leaving Bavarian Nordic
- Laurence de Moerlooze fratræder som EVP og Chief Medical Officer i Bavarian Nordic
More ▼
Key statistics
On Friday, Bavarian Nordic A/S (BV3A:FRA) closed at 7.65, -19.47% below its 52-week high of 9.50, set on Jun 14, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.50 |
---|---|
High | 7.65 |
Low | 7.50 |
Bid | 7.85 |
Offer | 8.75 |
Previous close | 7.50 |
Average volume | 0.00 |
---|---|
Shares outstanding | 234.35m |
Free float | 234.14m |
P/E (TTM) | 14.32 |
Market cap | 2.10bn USD |
EPS (TTM) | 0.6234 USD |
Data delayed at least 15 minutes, as of May 31 2024 14:29 BST.
More ▼